[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"breast-carcinoma-in-situ\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:breast-carcinoma-in-situ":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,48,83,115,145],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100524957","exert-bch-exercise-regimen-to-improve-muscle-mass-after-treatment-of-breast-cancer-100524957",false,"NCT06115486","EXERT-BCH Exercise Regimen to Improve Muscle Mass After Treatment of Breast Cancer","EXERT-BCH: Prospective Study of EXErcise Regimens After Treatment for Breast Cancer to Improve Hypertrophy","Inclusion Criteria:\n\nAge 20-89 years\n\n* Women with a biopsy proven diagnosis of ductal carcinoma in situ or invasive carcinoma of the breast\n* Women must have undergone treatment for breast cancer, including one or more of the following: surgery, radiation therapy, chemotherapy, immunotherapy, or hormonal therapy. Women undergoing active chemotherapy are not allowed on study. Immunotherapy or targeted agent usage is allowed.\n\nExclusion Criteria:\n\n* Any current treatment with cytotoxic chemotherapy for breast cancer\n* Inability to safely engage in group sessions of resistance training as deemed by study PI\n* Severe arthritic, joint, cardiovascular, or musculoskeletal condition deemed by PI to be unsafe to engage in resistance training","FEMALE","20 Years","89 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","The purpose of this research study is to evaluate the outcomes of two standard of care group exercise regimens to increase muscle mass in women who have been treated with breast cancer.",[27,28,29],"Breast Cancer","Breast Carcinoma in Situ","Breast Cancer Female",[31,32,33,34],"Cancer","Carcinoma in Situ","Hypertrophy","Exercise","RECRUITING","2026-02-02",{"date":38,"type":39},"2026-02-04","ACTUAL",{"date":41,"type":39},"2024-01-09",{"date":43,"type":21},"2027-01",{"name":45,"class":46},"Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":16,"minAge":57,"maxAge":58,"enrollmentInfo":59,"targetDuration":4,"studyType":22,"phases":61,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":82},"100256720","women-informed-to-screen-depending-on-measures-of-risk-wisdom-study-100256720","NCT02620852","Women Informed to Screen Depending on Measures of Risk (Wisdom Study)","Enabling a Paradigm Shift: A Preference-Tolerant RCT of Personalized vs. Annual Screening for Breast Cancer (Wisdom Study)","WISDOM","Inclusion Criteria:\n\n1. Female\\*\n2. Age 30 years to 74 years old\\*\\*\n3. Reside in the United States\\*\\*\\*\n\nNOTE\\*: As of 2019, we are now enrolling all persons who identify as female, and will capture both their sex at birth and gender identity in the baseline survey.\n\nNOTE\\*\\*: Eligibility from 2016 - October 2023 included ages 40-74 (WISDOM 1.0) and expanded to age 30 in October 2023 (WISDOM 2.0).\n\nNOTE\\*\\*\\*: As of 2019, recruitment is available nationwide. Original eligibility was limited to California, North Dakota, South Dakota, Iowa, Minnesota, Alabama, Louisiana, Illinois OR have coverage from a participating health plan.\n\nExclusion Criteria:\n\n1. Prior Breast cancer or ductal carcinoma in situ (DCIS) diagnosis\n2. Prior prophylactic bilateral mastectomy\n3. Inability to provide consent\n4. Non-English or Spanish proficiency (Spanish participation available: June 2019)",true,"30 Years","74 Years",{"count":60,"type":21},100000,[24],"Most physicians still use a one-size-fits-all approach to breast screening in which all women, regardless of their personal history, family history or genetics (except BRCA carriers) are recommended to have annual mammograms starting at age 40. Mammograms benefit women by detecting cancers early when they are easier to treat, but they are not perfect. Recent news stories have discussed some of the potential harms: large numbers of positive results that cause stressful recalls for additional mammograms and biopsies. With the current screening approach, half of the women who undergo annual screening for ten years will have at least one false positive biopsy. Potentially more important are cancer diagnoses for growths that might never come to clinical attention if left alone (called \"overdiagnosis\"). This can lead to unnecessary treatment. Even more concerning is evidence that up to 20% of breast cancers detected today may fall into the category of \"overdiagnosis.\"\n\nThe WISDOM 1.0 study compares annual screening with a risk-based breast cancer screening schedule, based upon each woman's personal risk of breast cancer. The investigators have designed the study to be inclusive of all, so that even women who might be nervous about being randomly assigned to receive a particular type of care (a procedure that is typical in clinical studies) will still be able to participate by choosing the type of care they receive.\n\nFor participants in the risk-based screening arm, each woman will receive a personal risk assessment that includes her family and medical history, breast density measurement and tests for genes (mutations and variations) linked to the development of breast cancer. Women who have the highest personal risk of developing breast cancer will receive more frequent screening, while women with a lower personal risk would receive less frequent screening. No woman will be screened less than is recommended by the USPSTF breast cancer screening guidelines.\n\nIf this study is successful, women will gain a realistic understanding of their personal risk of breast cancer as well as strategies to reduce their risk, and fewer women will suffer from the anxiety of false positive mammograms and unnecessary biopsies. The investigators believe this study has the potential to transform breast cancer screening in America.\n\nStarting in Spring 2023, WISDOM's design shifted to remove the randomized option, but will continue with the preference\u002Fself-selection option for participation (WISDOM 2.0). Participants will therefore continue to choose their study arm (Personalized or Annual) rather than have the option to be randomized. This study design change was made after review of the WISDOM 1.0 data by an independent monitoring committee, which indicates that personalized screening does not cause harm. WISDOM 2.0 has also lowered the eligibility to ages 30-74. Women ages 30-39 will only be offered to join the Personalized Arm.",[64,28,27],"Breast Cancer Screening",[66,67,68,69,70,71,72],"Breast screening","mammography","prevention","risk assessment","DCIS","Breast cancer","Wisdom","2025-11-19",{"date":75,"type":39},"2025-11-25",{"date":77,"type":39},"2016-08-31",{"date":79,"type":21},"2026-09-01",{"name":81,"class":46},"University of California, San Francisco",11,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":16,"minAge":91,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":22,"phases":95,"briefSummary":96,"conditions":97,"keywords":99,"overallStatus":105,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":47},"100532795","the-added-value-of-contrast-enhanced-mammography-to-standard-mammography-in-assessing-the-extent-of-dcis-100532795","NCT06217458","The Added Value of Contrast Enhanced Mammography to Standard Mammography in Assessing the Extent of DCIS","The Added Value of Contrast Enhanced Mammography (CEM) to Standard Mammography in Assessing the Extent of Ductal Carcinoma in Situ (DCIS)","CEMinDCIS","Inclusion Criteria:\n\n* Patients with pathohistological diagnosis of ductal in situ carcinoma based on samples obtained by vacuum-assisted breast biopsy (VABB) or ultrasound-guided breast biopsy (CNB)\n* Presented at the meeting of the multidisciplinary breast team of the Clinical Hospital Center in Rijeka\n* Patients who underwent surgery at CHC Rijeka and whose pathohistological diagnosis in the final PH report was pure DCIS or microinvasive breast cancer (DCIS with microinvasion)\n* Patients who agree to participate in the study\n\nExclusion Criteria:\n\n* Patients with contraindications for CEM: renal insufficiency (which is ruled out by presenting creatinine and\u002For eGFR results), iodine allergy, pregnancy\u002Flactation, hyperthyroidism\n* Patients who have undergone a preoperative breast MRI\n* Patients who have both DCIS and invasive carcinoma in the preoperative PH report or the final PH report of the surgical material, with the exception of foci with microinvasion (\\\u003C 1 mm).\n* Patients with ipsilateral DCIS recurrence or with previous ipsilateral breast surgery for invasive cancer.\n* Patients\u002Fsubjects whose CEMs do not correspond to the diagnostic interpretation for technical reasons are excluded from the study: insufficient positioning, contrast agent extravasation, failed subtraction\n* Patients under 18 years of age","18 Years","99 Years",{"count":94,"type":21},100,[24],"The study hypothesis is that the rate of inadequate surgical margins after conservative breast surgery for DICS and the rate of reoperation (re-excision or\u002Fand mastectomy) is lower in the group of patients who underwent standard preoperative mammography and CEM to assess the extent of DICS, compared to the group of patients for whom the preoperative assessment of the extent of in situ breast cancer was not performed using one of the imaging techniques with contrast medium such as contrast mammography or magnetic resonance imaging.",[70,28,98],"Calcification",[100,101,102,103,104],"Ductal in situ carcinoma","Calcifications","Breast surgery","Screening","Contrast Enhanced Mammography","NOT_YET_RECRUITING","2025-01-03",{"date":108,"type":39},"2025-01-06",{"date":110,"type":21},"2025-03-01",{"date":112,"type":21},"2027-01-01",{"name":114,"class":46},"Clinical Hospital Center Rijeka",{"id":116,"slug":117,"hasResults":11,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":16,"minAge":91,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":125,"phases":4,"briefSummary":126,"conditions":127,"keywords":130,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":144},"100546925","oncologic-cosmetic-and-patient-reported-outcomes-in-value-based-breast-surgery-oncopro-value-100546925","NCT06401304","Oncologic, Cosmetic and Patient Reported Outcomes in Value-Based Breast Surgery (OnCoPRO Value)","Oncologic, Cosmetic and Patient Reported Outcomes in Value-Based Breast Surgery. A Multicentre, Cohort Study","OncoPROValue-1","Inclusion Criteria:\n\n1. Female aged above 18 years.\n2. Signed and dated written informed consent before the start of specific protocol procedures; oral consent for the participants of the quality control retrospective cohort study before accepting to partake a telephone interview.\n3. Patients with invasive breast cancer (IBC) or ductal cancer in situ (DCIS) or unclear lesions mandating surgical excision or benign lesions amenable for surgical resection with BCS.\n4. ECOG performance status 0-2.\n\nExclusion Criteria\n\n1. Life expectancy of less than 6 months\n2. Non candidate for breast conservation\n3. Inability to understand given information and give informed consent or undergo study procedures",{"count":124,"type":21},1200,"OBSERVATIONAL","The study aspires to provide outcomes on surgery, quality of life and time-to-event outcomes following the development and validation of a standardised surgical assessment tool in a shared decision-making framework for patients with pre-invasive or invasive breast cancer with breast conservation.",[27,28,128,129],"Breast Cancer Invasive","Breast Asymmetry",[131,132,133,134],"Oncoplastic breast conservation","Breast Conserving Surgery","Patient reported outcomes","Shared decision making","2024-05-02",{"date":137,"type":39},"2024-05-06",{"date":139,"type":39},"2020-01-01",{"date":141,"type":21},"2032-12-30",{"name":143,"class":46},"Uppsala University",3,{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":152,"minAge":91,"maxAge":4,"enrollmentInfo":153,"targetDuration":155,"studyType":125,"phases":4,"briefSummary":156,"conditions":157,"keywords":160,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":47},"100408802","registry-for-intra-operative-radiotherapy-during-breast-conserving-surgery-in-patients-with-early-stage-breast-cancer-100408802","NCT04603209","Registry for Intra-Operative Radiotherapy During Breast Conserving Surgery in Patients With Early Stage Breast Cancer","Research Registry for Intra-Operative Radiotherapy (IORT) During Breast Conserving Surgery in Patients With in Situ and Early Stage Breast Cancer","Inclusion Criteria:\n\n* Clinical stage Tis, T1, or T2(≤ 3cm), N0, M0 (AJCC Classification)\n* Unifocal Disease\n* Candidate for breast-conserving surgery\n* Recommended treatment by multidisciplinary team\n\nExclusion Criteria:\n\n* Clinical stage T3-4, N1-3, M1\n* Multifocal disease","ALL",{"count":154,"type":21},1000,"5 Years","This is a prospective, registry study that will enroll all women with early stage breast cancer who will be treated with intraoperative radiotherapy (IORT) during breast-conserving surgery. The purpose of this study is to further validate the long-term effectiveness and safety of this treatment method. We aim to assess short and long-term patient outcomes associated with IORT, including perioperative complications, local and distance disease recurrences, as well as disease-free survival and overall survival.",[158,28,159],"Early-stage Breast Cancer","Breast Neoplasms",[27,158,161,162],"Intraoperative Radiotherapy","IORT","2024-04-15",{"date":165,"type":39},"2024-04-16",{"date":167,"type":39},"2018-10-03",{"date":169,"type":21},"2028-10-03",{"name":171,"class":46},"Saint John's Cancer Institute"]